Company name
Arphamid Therapeutics SAS
Company profile
Arphamid Therapeutics is developing first-in-class RF-amide receptor antagonists targeting GPR103 and GPR10, two critical modulators of the brain's reward and hedonic systems. Our platform addresses high unmet medical needs in addiction, obesity, and anxiety/depression—markets with limited effective pharmacotherapies and significant global impact. In preclinical models, the RF-amide neuropeptide system orchestrates physiological functions linked to reward processing, food int
Date, time and room information
Tuesday, May 5, 13:45 - 15:00, room Singapore
Category
Emerging biotech company
Title of the presentation
Unlocking Novel Therapeutics for Addiction, Metabolic, and Mental Health Disorders Through the RF-Amide System
Speaker information
| Name | Position | Institution |
|---|---|---|
| Alexander Kraus | President & CEO | Arphamid Therapeutics SAS |
